Stocks
Fate Therapeutics, Inc.FATE
NASDAQHealthcareBiotechnology$2.31+0.00%
Price as of · delayed, not real-time
Developing immuno-oncology cell therapies using induced pluripotent stem cell (iPSC) technology, Fate Therapeutics focuses on creating off-the-shelf treatments for cancer. The biotech firm has faced significant volatility as its clinical-stage pipeline progresses, making it a high-risk, high-reward play for investors in cell therapy.
Market Cap: $136.0M52W Range: $0.94-$3.23
Congressional Interest in Fate Therapeutics, Inc. (FATE)
1 member of Congress has disclosed 1 trade in Fate Therapeutics, Inc. (FATE), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading FATE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-01-31 | Daniel Goldman | sell | $1K-$15K |